Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parkinson's disease: past, present, and future

I J Kopin1

  • 1Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|August 1, 1993
PubMed
Summary

Parkinson's disease treatment has advanced significantly, from dopamine replacement with levodopa to exploring neuroprotective strategies and regenerative therapies like tissue implants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catecholaminergic inhibition by hypercortisolemia in the paraventricular nucleus of conscious rats.

Endocrinology·1995
Same author

Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines.

The Journal of clinical endocrinology and metabolism·1995
Same author

Decreased central and peripheral catecholaminergic activation in obese Zucker rats.

Endocrinology·1995
Same author

Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968.

Pharmacopsychiatry·1995
Same author

Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.

Journal of neurochemistry·1995
Same author

Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats.

Journal of the autonomic nervous system·1995

Area of Science:

  • Neurologic science and neurodegenerative disease research.
  • Pharmacology and neurotransmitter replacement therapy.
  • Neurobiology of movement disorders.

Background:

  • Parkinson's disease (PD) understanding has evolved from clinical observation to molecular insights.
  • Early treatments focused on symptomatic relief, awaiting deeper pathophysiological understanding.
  • The central nervous system's complexity posed challenges for effective PD therapies.

Observation:

  • Discovery of dopamine deficit in basal ganglia was crucial for developing levodopa therapy.
  • 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) neurotoxin research spurred etiological investigations.
  • Inhibition of monoamine oxidase B (MAO-B) with deprenyl showed potential for disease modification.

Findings:

  • Levodopa remains a cornerstone treatment, enhanced by metabolic inhibitors.
  • Dopamine agonists offer therapeutic options but do not halt disease progression.
  • MPTP-induced parkinsonism models facilitate research into disease mechanisms and treatments.

Implications:

  • Tissue implantation strategies, including fetal mesencephalic grafts, show promise for PD reversal.
  • Research continues towards therapies that can arrest or slow the degenerative process in PD.
  • Advances in PD research may inform treatments for other neuropsychiatric disorders.

Related Experiment Videos